Insilico Medicine company information, Employees & Contact Information

Insilico Medicine gets $255 million to boost AI-powered R&D, announces a collaboration Bioengineer.org

Insilico Medicine’s CEO named Highly Cited Researchers of 2024 EurekAlert!

Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas PR Newswire

On November 20th, the renowned business magazine Fortune released its 2024 Fortune 50 AI Innovators list, highlighting the AI companies leading in the new phase of AI technology applications. EurekAlert!

Insilico Medicine’s Generative AI Pioneer Alex Zhavoronkov, PhD at Lab of the Future March 9 EurekAlert!

Insilico Medicine, Mabwell Bioscience, and ChemExpress forging ahead with ADC innovation through strategic collaboration EurekAlert!

Insilico Medicine leadership to attend 42nd Annual J.P. Morgan Healthcare Conference EurekAlert!

Insilico Medicine announces Pharma.AI week webinar series: Revolutionizing drug discovery with cutting-edge AI innovations EurekAlert!

Pharma.ai summer 2025 updates: Join Insilico Medicine on July 10 for the future of AI-empowered medical research boost EurekAlert!

Insilico Medicine announces positive topline results of ISM001-055 for the treatment of idiopathic pulmonary fibrosis (IPF) developed using generative AI EurekAlert!

Insilico Medicine opens largest AI-powered biotechnology research center in the Middle East EurekAlert!

Join Us at ATS | Insilico Medicine Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference EurekAlert!

Generative AI against diseases: Insilico Medicine announced Pharma.AI-powered HPK1 inhibitor series in peer-reviewed publication trilogy, as potential immunotherapy options EurekAlert!

Insilico Medicine secures $110 million Series E financing to advance AI-driven drug discovery innovation EurekAlert!

Insilico Medicine received IND approval and orphan drug designation from FDA for ISM6331, an AI-designed TEAD inhibitor targeting solid tumors and mesothelioma EurekAlert!

Insilico Medicine achieves a milestone in AI-facilitated drug discovery collaboration with Sanofi EurekAlert!

Harbour BioMed and Insilico Medicine achieve strategic collaboration to advance AI-driven antibody discovery and development EurekAlert!

Insilico Medicine launches 6th generation Intelligent Robotics Lab to further accelerate its AI-driven drug discovery EurekAlert!

Insilico Medicine deploys the first bipedal humanoid AI scientist in the fully-robotic drug discovery laboratory EurekAlert!

Advanced Science: Insilico Medicine utilized AI technology for novel target discovery and drug repurposing to treat endometriosis EurekAlert!

First end-to-end generative AI-assisted drug ISM001-055 receives official generic name Rentosertib from USAN EurekAlert!

Insilico Medicine and UAE University achieve collaboration to foster local talent and academic innovation EurekAlert!

Insilico Medicine appoints Dr. Feng Ren as co-CEO PR Newswire

Transforming Parkinson’s disease treatment, Insilico Medicine announces IND-enabling completion for AI-empowered oral NLRP3 inhibitor ISM8969 EurekAlert!

Insilico Medicine CEO Alex Zhavoronkov featured among World’s Top 50 Innovators EurekAlert!

Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI PR Newswire

Insilico Medicine completes first-in-patient dosing of ISM3412, the novel MAT2A inhibitor for the treatment of locally advanced/metastatic solid tumors EurekAlert!

Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer PR Newswire

Menarini Group and Insilico Medicine enter a second exclusive global license agreement for an AI discovered preclinical asset targeting high unmet needs in oncology EurekAlert!

Insilico Medicine announces first patient dosed in phase I clinical trial of ISM6331, the novel inhibitor for the treatment of mesothelioma and other solid tumors EurekAlert!

Insilico Medicine reports positive Phase IIa results for ISM001-055, a novel first-in-class drug treatment for idiopathic pulmonary fibrosis (IPF) designed using generative AI EurekAlert!

Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets PR Newswire

Insilico Medicine presents data on AI-designed cancer drugs at 3 major cancer conferences EurekAlert!

COSMIC: Molecular Conformation Space Modeling in Internal Coordinates with an Adversarial Framework ACS Publications

Insilico Medicine Announces Strategic Collaboration with EQRx to Jointly Advance AI-driven Drug Discovery, Development and Commercialization for Multiple Targets PR Newswire

Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs PR Newswire

Targeting synthetic lethality, Insilico Medicine nominates WRN small molecule pre-clinical candidate for MSI-H cancers EurekAlert!

AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine PR Newswire

Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus PR Newswire

Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion GlobeNewswire

(IMAGE) EurekAlert!

CTFH and Insilico Medicine Enter Al Drug Discovery Collaboration Focused On Accelerating First-in-Class Therapeutics, Worth Up to $200 million PR Newswire

Insilico raises $37M with plans to bring its AI to more drug discovery partnerships Fierce Biotech

Insilico Medicine to co-organize and present new research data at the Aging Forum at BLSW Bioengineer.org

Insilico Medicine to showcase its AI Engine for Future Drug Discovery at the 2018 Future Tech Forum Bioengineer.org

Insilico Medicine and Westlake Pharma Announce Cooperation Relationship on Accelerating the Innovative Drugs R&D for Novel Coronavirus - PR Newswire APAC 美通社

iPANDA: A novel approach for precision medicine and drug discovery on gene expression data Bioengineer.org